BioSpace News Archive

TRACON Pharmaceuticals, Inc. announced that it has commenced court proceedings in Hong Kong and the Cayman Islands to enforce an April 2023 arbitration award against I-Mab for approximately $23.0 million, plus interest.

Sensus Healthcare, Inc. announces its participation in the Maxim Group Virtual Healthcare Conference hosted by M-Vest.

Cardinal Health announced its plans to build a new distribution center in the Greenville, South Carolina, area, to support its at-Home Solutions business, a market-leading home healthcare medical supplies provider serving people with chronic and serious health conditions in the United States.

Vatech, a global leader in the dental imaging market, reported that the digital Intraoral x-ray generator ‘EzRay Air’ series has already been adopted by 50,000 dentists around the world.

Novavax, Inc. announced that the Company has adjourned its 2023 Annual Meeting of Stockholders, originally scheduled to be held on June 15, 2023, to July 11, 2023 at 8:30 a.m., Eastern Time.

DepYmed, Inc. is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase family of enzymes.

SyntheticMR has released a new update to SyMRI 11.3.11 & 12.1.11 that provides condensed and relevant quantitative neuro report for both radiologists and providers.

NS Pharma, Inc. announced the U.S. Food & Drug Administration has agreed to the planned Phase I/II study of NS-050/NCNP-03, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 50 skipping therapy.

InnoCare Pharma, a leading biopharmaceutical company, announced the latest clinical data of its Bruton Tyrosine Kinase inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma.

Takeda and HUTCHMED Limited announced that the European Medicines Agency has validated and accepted for regulatory review the marketing authorization application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer.